A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
Study sponsor: Cytokinetics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-07-18Actual
Enrollment · participants489Actual
Source updated2024-12-05Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.